Pro Medicus (PME.AX) Aandeel Koers
Pro Medicus Koers
De omzet is de afgelopen 19 jaar met 17,3% per jaar gegroeid tot 261,69 Miljoen AUD. De winst per aandeel is de afgelopen 19 jaar met 20,8% per jaar gegroeid. De nettowinstmarge van Pro Medicus ligt op 101,4% en is ten opzichte van 47,6% enkele jaren eerder gestegen. Pro Medicus biedt momenteel een dividendrendement van circa 0,45%. De uitkeringsratio ligt rond 73% van de winst. Het dividend is de afgelopen 19 jaar met 21,6% per jaar gegroeid. Analisten hanteren een mediaan koersdoel van 244,80 AUD — dat impliceert 23,4% boven de huidige koers. Van de 17 analisten geven 11 het aandeel een koopadvies — per saldo een Kopen-consensus.
Pro Medicus aandeelkoers
Deze data ophalen via de Eulerpool API
100.000 requests/maand gratis · geen creditcard
Pro Medicus bedrijfsmodel & aandelenanalyse
Veelgestelde vragen over Pro Medicus
The business model of Pro Medicus Ltd revolves around providing advanced healthcare imaging software solutions. The company specializes in developing and delivering a comprehensive range of radiology solutions that enhance workflow efficiency and improve patient care. Pro Medicus offers cutting-edge products like Visage AI, Visage 7, and Visage RIS, which allow healthcare professionals to efficiently manage and analyze medical images. By combining innovative technology with a customer-centric approach, Pro Medicus helps healthcare providers worldwide optimize their imaging operations and deliver accurate diagnoses. With its focus on developing state-of-the-art software solutions, Pro Medicus positions itself as a leader in the medical imaging industry.
Pro Medicus Ltd is primarily active in the healthcare industry.
The main competitors of Pro Medicus Ltd in the market include other medical imaging companies such as Carestream Health, Change Healthcare, and Sectra AB. These companies also specialize in providing medical imaging solutions and technology to healthcare providers and are prominent players in the industry. Pro Medicus Ltd competes with them in terms of product offerings, innovation, customer base, and market share.
Pro Medicus Ltd is a renowned healthcare imaging and information technology provider. Established in 1983, the company has a rich history of pioneering innovative solutions in the medical imaging industry. With a strong focus on radiology, Pro Medicus has developed advanced imaging software that improves efficiency and enhances patient care. The company's success is attributed to its commitment to research and development, resulting in cutting-edge technologies and multiple industry awards. Pro Medicus operates globally, serving prominent healthcare institutions and professionals. With its profound expertise and dedication to advancing medical imaging technology, Pro Medicus Ltd continues to lead the industry in providing innovative solutions for the healthcare sector.
Some significant milestones achieved by Pro Medicus Ltd include the successful expansion into major global markets, such as the United States and Europe, further solidifying its position as a leading provider of healthcare imaging solutions. The company has also experienced continuous revenue growth, achieving record-breaking financial results year after year. Pro Medicus Ltd has consistently developed and released innovative software solutions, enhancing efficiency and productivity for healthcare professionals. Additionally, the company has formed strategic partnerships with top-tier healthcare organizations, further establishing its reputation as a trusted industry leader. These accomplishments have propelled Pro Medicus Ltd's growth and success in the competitive healthcare technology sector.
Pro Medicus Ltd primarily operates in Australia and the United States.
Pro Medicus Ltd is a leading healthcare IT solutions provider with a strong commitment to excellence and innovation. The company's core values revolve around delivering exceptional products and services that empower healthcare professionals to enhance patient care and outcomes. Pro Medicus emphasizes a customer-centric approach and strives to provide customized solutions tailored to meet the unique needs of its clients. With a clear focus on technological advancements and high-quality imaging software, Pro Medicus constantly pushes the boundaries in the healthcare industry. By fostering a culture of collaboration and continuous improvement, Pro Medicus Ltd is dedicated to transforming the way medical images are managed and shared worldwide.
Analisten hanteren momenteel een gemiddeld koersdoel van 226,59 AUD voor het aandeel Pro Medicus (mediaan: 244,80 AUD), oftewel +14,2 % ten opzichte van de laatste koers. De consensus is gebaseerd op 17 analistenratings.
17 analisten beoordelen het aandeel Pro Medicus momenteel: 13 adviseren kopen, 4 houden en 0 verkopen.
Omgezet tegen de huidige wisselkoers noteert het aandeel Pro Medicus op 124,36 EUR (198,38 AUD).
Het aandeel Pro Medicus (PME.AX) is genoteerd aan 3 beurzen, waaronder: ASX (PME.AX), Frankfurt (PMC.F).
Pro Medicus Ltd is a global company specializing in providing advanced IT solutions for the healthcare industry. They offer innovative information and image management solutions that are used by leading healthcare organizations worldwide. Their main divisions include Picture Archiving and Communication Systems (PACS), Radiology Information Systems (RIS), and Telemedicine. Their PACS solutions allow hospitals and healthcare organizations to store, manage, and share digital images from medical diagnostic devices such as CT, MRI, and X-ray machines. These solutions are scalable and provide high-quality image quality for radiologists and other specialists to make informed diagnoses. Their RIS is an integrated solution designed specifically for radiology departments and practices, providing complete patient and order management, as well as integrated workflow tools to improve the efficiency and accuracy of diagnosing and evaluating medical imaging data. Their telemedicine solutions enable radiology professionals to edit and share medical images remotely over the internet, particularly beneficial in facilities with limited resources or for quick access to medical images in emergency diagnoses. In addition, Pro Medicus Ltd also offers specialized solutions for clinical decision support, automated medical image analysis, and patient management. Their clinical decision support provides assistance to medical professionals in diagnosis and treatment monitoring, while the automated analysis of medical image data allows for the quick processing of large amounts of data, producing results that can be utilized by professionals for diagnostic purposes. Their patient management solutions provide comprehensive capture and management of health data that can be used by doctors and other professionals to develop better treatment options for their patients. Pro Medicus Ltd is a global company with a strong focus on research and development. They have partnerships with leading healthcare organizations worldwide and possess a strong portfolio of intellectual property. Their business model is based on the sale of products and services specifically designed for the needs of the healthcare industry. The company emphasizes innovation, customer satisfaction, and delivering high-quality solutions that are scalable and flexible for various users. Overall, Pro Medicus Ltd is an innovative market leader in the field of medical IT solutions. They are globally recognized for their products and services and are expected to continue playing a significant role in the healthcare industry.
De omzet van Pro Medicus bedraagt 261,69 Miljoen AUD. Deze cijfers zijn gebaseerd op huidige financiële gegevens en weerspiegelen de bedrijfsresultaten van het bedrijf.
De winst van Pro Medicus bedraagt 265,34 Miljoen AUD. De nettowinst weerspiegelt de rentabiliteit van het bedrijf na aftrek van alle kosten.
De koers-winstverhouding (P/E) van Pro Medicus bedraagt momenteel 78,23. De P/E-ratio vergelijkt de huidige aandeelkoers met de winst per aandeel en helpt beleggers de waardering van het Pro Medicus-aandeel in te schatten.
De koers-omzetverhouding (P/S) van Pro Medicus bedraagt momenteel 79,32. De P/S-ratio vergelijkt de marktkapitalisatie met de jaarlijkse opbrengsten en dient als waarderingsmaatstaf voor het Pro Medicus-aandeel.
De Eulerpool Kwaliteitsscore voor Pro Medicus is 8/10.
De ISIN van Pro Medicus is AU000000PME8. De ISIN (International Securities Identification Number) is een wereldwijd unieke identificatie voor wertpapieren.
De WKN van Pro Medicus is 591723. De WKN (Wertpapierkennnummer) is een zescijferig Duits identificatienummer voor wertpapieren.
Het tickersymbool van Pro Medicus is PME.AX. Onder dit beurstickersymbool wordt het Pro Medicus-aandeel op de beurs verhandeld.
Pro Medicus aandeel
Pro Medicus Peer Group
Pro Medicus Ticker
Pro Medicus FIGI
Alle fundamentals en diepgaande analyse van Pro Medicus
Onze aandelenanalyse van het Pro Medicus-aandeel omvat belangrijke financiële kerncijfers zoals de omzet, de winst, de P/E-ratio, de P/S-ratio, de EBIT, evenals informatie over het dividend. Daarnaast bekijken we aspecten zoals aandelen, marktkapitalisatie, schulden, eigen vermogen en verplichtingen van Pro Medicus. Als u meer gedetailleerde informatie zoekt over deze onderwerpen, bieden we op onze subpagina's uitgebreide analyses: